"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma
(HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer
cells escaping from immune surveillance and constructs an immunosuppressive microenvironment.
Correspondingly, multiple signals loaded dendritic cells vaccine can efficiently present T
cells with antigens of HCC sensitize their antitumor properties meanwhile low dose
cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Therefore, we
put forward a new scientific therapy called "multiple signals loaded dendritic cells vaccine
combined low dose of cyclophosphamide" combining with radical surgery or TACE or targeted
agents for patients with hepatocellular carcinoma to prolong their survival time.
Phase:
Phase 2
Details
Lead Sponsor:
Yuehua Huang
Collaborators:
Nanfang Hospital of Southern Medical University Sun Yat-sen University